Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

by @JTC_PALIdev | May 14, 2024 | Press Releases

– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to execute on business plan and reach clinical and regulatory...

Palisade Bio Appoints Margery Fischbein to its Board of Directors

by @JTC_PALIdev | May 7, 2024 | Press Releases

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”,...

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

by @JTC_PALIdev | May 7, 2024 | Press Releases

Carlsbad, CA, May 07, 2024 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed...

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

by @JTC_PALIdev | May 2, 2024 | Press Releases

Carlsbad, CA, May 02, 2024 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered...

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

by @JTC_PALIdev | May 1, 2024 | Press Releases

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the...

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

by @JTC_PALIdev | Apr 23, 2024 | Press Releases

– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on...